Hjem › Multipelt myelom › District of Columbia › Washington
Kliniske studier for Multipelt myelom i Washington, DC
22 studier for Multipelt myelom søker deltakere på steder i og rundt Washington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RekruttererFase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruttererFase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RekruttererFase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Tissue Collection for Studies of Lymph Cancer
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RekruttererFase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi unna
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruttererFase 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mi unna
18F-Fluciclovine PET/CT in Multiple Myeloma
RekruttererFase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruttererFase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi unna
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
RekruttererFase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
RekruttererObservasjonsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi unna
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekruttererFase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RekruttererFase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
RekruttererFase 2
- GSK Investigational Site, Bethesda · 7 mi unna
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RekruttererFase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Rekrutterer
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 mi unna
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RekruttererFase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi unna
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruttererFase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RekruttererFase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruttererFase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Multipelt myelom-studier i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA42 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Edison, NJ22 studier
Andre studier i Washington
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft55 studier
- Brystkreft46 studier
- Metastatisk kreft43 studier
- Lungekreft41 studier
- Prostatakreft38 studier
- Fedme33 studier
- Kolorektal kreft29 studier
- Kardiovaskulær sykdom28 studier
- Blærekreft26 studier
- Akut myelogen leukemi24 studier
- Eggstokkreft23 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.